Consort Medical PLC AGM Voting Update - Director Declaration (4076P)
08 February 2019 - 12:28AM
UK Regulatory
TIDMCSRT
RNS Number : 4076P
Consort Medical PLC
07 February 2019
Registered Number 406711
Consort Medical plc
AGM Voting Update - Director Declaration
The Board of Consort Medical plc (the 'Company') has reviewed
the feedback received from certain shareholders on their reasons
for voting against the re-election of Mr Ian Nicholson to the Board
at the AGM held in September 2018 in respect of which a vote of
more than 20% against was received.
The Board understand that the one issue of concern was Ian's
reappointment to the Remuneration Committee during 2018 in respect
of which it was felt that Mr Nicholson could not be considered an
independent non-executive Director due to his relationship as a
consultant to the Group between March to April 2017, when Mr
Nicholson provided three days of consultancy services in respect of
a potential acquisition opportunity.
The Board has listened to and respects the views of its
shareholders on this issue. Accordingly, and in accordance with
Rule 9.6.11 (3) of the UK Listing Rules, the Company gives notice
that following a review of the Remuneration Committee Membership it
has been agreed that Mr Nicholson will step down from the
Remuneration Committee with immediate effect.
Enquiries:
Consort Medical plc
Andrew Jackson
01442 867920
Consort Medical plc is a leading one-stop developer and
manufacturer of drugs and premium drug delivery devices. We partner
with pharmaceutical businesses in providing innovative life
improving treatments to patients across the world through two
integrated activities:
The design, development and manufacture of high performance
medical devices for inhaled, injectable, nasal and ocular drug
delivery, as well as point of care diagnostics products.
The development, formulation and manufacture of active
pharmaceutical ingredients (APIs) and finished dose drugs to the
highest quality standards.
We employ over 2,000 people globally and are committed to
investing in patient, clinician and customer driven innovation to
create new treatments.
Consort Medical is a public company quoted on the premium list
of the London Stock Exchange (LSE:CSRT) and is organised in two
divisions: Bespak and Aesica.
www.consortmedical.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEADAXEAKNEFF
(END) Dow Jones Newswires
February 07, 2019 08:28 ET (13:28 GMT)
Consort Medical (LSE:CSRT)
Historical Stock Chart
From Apr 2024 to May 2024
Consort Medical (LSE:CSRT)
Historical Stock Chart
From May 2023 to May 2024